Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Sezzle Inc (SEZL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Sezzle Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Sezzle Inc trades at $169.8 (market cap $5.97B). The key difference: Sezzle Inc is the larger of the two by market cap, and Sezzle Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | SEZL | |
|---|---|---|
Market Cap | $4.49B | $5.97B |
Sector | Health | Technology |
52-Week High | $28.06 | $183.24 |
52-Week Low | $20.06 | $50.97 |
Enterprise Value | $3.69B | $6.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Sezzle (SEZL) trades at $179.05, down 2.29% today, but maintains a strong bullish technical trend with moving averages supporting further upside. Fundamentally, the company exhibits robust profitability with a 30.83% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights product expansion and strong Q1 2026 results, driving positive sentiment.
The outlook remains positive given accelerating revenue growth and raised guidance, though risks include potential securities litigation and high valuation multiples. Analysts are predominantly bullish with a consensus price target of $146.40, suggesting caution near-term, but operational momentum supports long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
